Transparency Market Research has published a new report titled "Pulmonary Arterial Hypertension Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" to its report store.
Albany, NY -- (SBWIRE) -- 04/13/2015 -- Pulmonary arterial hypertension (PAH) is a progressive disorder, characterized by high blood pressure in pulmonary arteries that carry blood from the heart to the lungs. PAH is a very rare condition that occurs when pulmonary arteries become narrow in diameter or get blocked. This report on the global pulmonary arterial hypertension (PAH) market offers an insightful and in-depth assessment of the current and future market potential of PAH drugs. The research study has been divided into eight chapters namely, preface, executive summary, global PAH market overview, global PAH market revenue by drug class, PAH market pipeline analysis, global PAH market revenue by geography, recommendations, and company profiles.
Browse Pulmonary Arterial Hypertension Market Report with Full TOC at http://www.transparencymarketresearch.com/pulmonary-arterial-hypertension-therapeutics.html
The executive summary chapter covers a market snapshot representing key findings from the study on the global PAH market. The market overview chapter of the report comprises qualitative analysis of the overall PAH market, considering factors determining market dynamics such as growth drivers, restraints, and opportunities. This chapter also includes a section on epidemiology of PAH. A section on the event impact analysis has also been provided in the market overview chapter of the report on the PAH market. In the competitive landscape section, the market revenue share of key players operating in the PAH market in terms of percentage in 2013 has been provided. The market share analysis of key players involved a study of the company's product/service portfolio and sales revenue along with the geographical presence.
In chapter four, the global PAH market has been segmented into prostacyclin and prostacyclin analogs, endothelin receptor antagonists (ERAs), phosphodiesterase-5 (PDE-5) inhibitors, and soluble guanylate cyclase (sGC) stimulators, based on the commercially-available drug classes, to treat PAH. The market revenue size for each segment has been provided in terms of USD million in the chapter for the period from 2012 to 2020, along with the CAGR for the forecast period between 2014 and 2020, considering 2012 and 2013 as the base years. The chapter also provides qualitative analysis for each segment, based on factors such as market trends, recent developments, future outlook, and opportunities.
Request for sample report http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1181
Chapter five deals with the pipeline analysis of the PAH market and comprises information such as major steps involved in the development and commercialization of a drug, tabular presentation of early-stage drug candidates, and extensive analysis and future sales projection of the late-stage drug candidate, Uptravi (selexipag).
Geographically, the global PAH market has been classified into four major regions namely, North America, Europe, Asia-Pacific, and Rest of the World (RoW). The market size and forecast for each of these regions along with the CAGR has been provided in the report.
The study on the global PAH market also suggests a list of recommendations for new companies aspiring to enter the market and existing companies willing to accentuate revenue shares. The report concludes with the profiles of major players in the global PAH market such as Actelion Pharmaceuticals, Ltd., Bayer HealthCare, Gilead Sciences, Inc., GlaxoSmithKline plc, Novartis International AG, Pfizer, Inc., and United Therapeutics Corporation. Each company profile in the report provides information under the heads: company overview, financial overview, product portfolio, business strategies, and recent developments.
The company overview section comprises basic information about the company such as major business areas, company's brief history and its establishment year, number of employees, and geographical presence. In the financial overview section, annual revenue for the last three consecutive years (2011, 2012, and 2013) has been provided. The business strategies section mentions key strategies adopted by a company in the past to strengthen its position in the PAH market. The recent developments section shares information about the recent activities of the companies operating in the PAH market.
Press Release Of Pulmonary Arterial Hypertension Market http://www.transparencymarketresearch.com/pressrelease/pulmonary-arterial-hypertension-therapeutics-market.htm
The global PAH market is segmented as follows:
Global Pulmonary Arterial Hypertension Market, by Drug Class
Prostacyclin and Prostacyclin Analogs
Endothelin Receptor Antagonists (ERAs)
Phosphodiesterase-5 (PDE-5) Inhibitors
Soluble Guanylate Cyclase (sGC) Stimulators
Pipeline Analysis: Pulmonary Arterial Hypertension Market
Early-stage Drug Candidates (Phase I & Phase II)
Late-stage Drug Candidates (Phase III & Registration Phase)
Global Pulmonary Arterial Hypertension Market, by Geography
Rest of the World (RoW)
About Transparency Market Research
Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. We are privileged with highly experienced team of Analysts, Researchers, and Consultants, who use proprietary data sources and various tools and techniques to gather, and analyze information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.